TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness

References

• Still IH, Vettaikkorumakankauv AK, DiMatteo A, et al. Structure-function evolution of the transforming acidic coiled coil genes revealed by analysis of phylogenetically diverse organisms. BMC Evol Biol. 2004;4(1):16. doi: 10.1186/1471-2148-4-16
   PubMedGoogle Scholar
• Gergely F, Karlsson C, Still I, et al. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci U S A. 2000;97(26):14352–7. doi: 10.1073/pnas.97.26.14352
   PubMed Web of Science ®Google Scholar
• Gabillard JC, Ulisse S, Baldini E, et al. Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein. Biochem Biophys Res Commun. 2011;408(4):647–53. doi: 10.1016/j.bbrc.2011.04.078
   PubMed Web of Science ®Google Scholar
• LeRoy PJ, Hunter JJ, Hoar KM, et al. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora a activity. Cancer Res. 2007;67(11):5362–70. doi: 10.1158/0008-5472.CAN-07-0122
   PubMed Web of Science ®Google Scholar
• Dou Z, Ding X, Zereshki A, et al. TTK kinase is essential for the centrosomal localization of TACC2. FEBS Lett. 2004;572(1–3):51–6. doi: 10.1016/j.febslet.2004.06.092
   PubMed Web of Science ®Google Scholar
• Tien AC, Lin MH, Su LJ, et al. Identification of the substrates and interaction proteins of aurora kinases from a protein-protein interaction model. Mol & Cell Proteomics. 2004;3(1):93–104. doi: 10.1074/mcp.M300072-MCP200
   PubMed Web of Science ®Google Scholar
• Ha GH, Kim JL, Breuer EK. Transforming acidic coiled-coil proteins (TACCs) in human cancer. Cancer Lett. 2013;336(1):24–33. doi: 10.1016/j.canlet.2013.04.022
   PubMed Web of Science ®Google Scholar
• Chen HM, Schmeichel KL, Mian IS, et al. AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression. Mol Biol Cell. 2000;11(4):1357–67. doi: 10.1091/mbc.11.4.1357
   PubMed Web of Science ®Google Scholar
• Yoshida E, Terao Y, Hayashi N, et al. Promoter-level transcriptome in primary lesions of endometrial cancer identified biomarkers associated with lymph node metastasis. Sci Rep. 2017;7(1):14160. doi: 10.1038/s41598-017-14418-5
   PubMedGoogle Scholar
• Angrisano T, Lembo F, Pero R, et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 2006;34(1):364–372. doi: 10.1093/nar/gkj400
   PubMed Web of Science ®Google Scholar
• Saatci O, Akbulut O, Cetin M, et al. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. Cell Death Differ. 2023;30(5):1305–1319. doi: 10.1038/s41418-023-01140-1
   PubMed Web of Science ®Google Scholar
• Ertych N, Bastians H. Interaction of TACC3 and TSC2 at the nuclear envelope and mitotic structures. Cell Cycle. 2010;9(7):1231–1240. doi: 10.4161/cc.9.7.11257
   Web of Science ®Google Scholar
• Gomez-Baldo L, Schmidt S, Maxwell CA, et al. TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle. 2010;9(6):1143–55. doi: 10.4161/cc.9.6.11018
   PubMed Web of Science ®Google Scholar
• Thakur HC, Singh M, Nagel-Steger L, et al. The centrosomal adaptor TACC3 and the microtubule polymerase chTOG interact via defined C-terminal subdomains in an aurora-A kinase-independent manner. J Biol Chem. 2014;289(1):74–88. doi: 10.1074/jbc.M113.532333
   PubMed Web of Science ®Google Scholar
• Still IH, Hamilton M, Vince P, et al. Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon. Oncogene. 1999;18(27):4032–8. doi: 10.1038/sj.onc.1202801
   PubMed Web of Science ®Google Scholar
• Still IH, Vince P, Cowell JK. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics. 1999;58(2):165–70. doi: 10.1006/geno.1999.5829
   PubMed Web of Science ®Google Scholar
• Adnane J, Gaudray P, Dionne CA, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 1991;6(4):659–663.
   PubMed Web of Science ®Google Scholar
• Kiemeney LA, Sulem P, Besenbacher S, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet. 2010;42(5):415–9. doi: 10.1038/ng.558
   PubMed Web of Science ®Google Scholar
• Piekorz RP, Hoffmeyer A, Duntsch CD, et al. The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J. 2002;21(4):653–664. doi: 10.1093/emboj/21.4.653
   PubMed Web of Science ®Google Scholar
• Sadek CM, Pelto-Huikko M, Tujague M, et al. TACC3 expression is tightly regulated during early differentiation. Gene Expr Patterns. 2003;3(2):203–211. doi: 10.1016/s1567-133x(02)00066-2
   PubMed Web of Science ®Google Scholar
• Conte N, Charafe-Jauffret E, Delaval B, et al. Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. Oncogene. 2002;21(36):5619–30. doi: 10.1038/sj.onc.1205658
   PubMed Web of Science ®Google Scholar
• Cully M, Shiu J, Piekorz RP, et al. Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis. Cancer Res. 2005;65(22):10363–70. doi: 10.1158/0008-5472.CAN-05-1633
   PubMed Web of Science ®Google Scholar
• Schuendeln MM, Piekorz RP, Wichmann C, et al. The centrosomal, putative tumor suppressor protein TACC2 is dispensable for normal development, and deficiency does not lead to cancer. Mol Cell Biol. 2004;24(14):6403–9. doi: 10.1128/MCB.24.14.6403-6409.2004
   PubMed Web of Science ®Google Scholar
• Lauffart B, Gangisetty O, Still IH. Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2. Genomics. 2003;81(2):192–201. doi: 10.1016/s0888-7543(02)00039-3
   PubMed Web of Science ®Google Scholar
• Cheng S, Douglas-Jones A, Yang X, et al. Transforming acidic coiled-coil-containing protein 2 (TACC2) in human breast cancer, expression pattern and clinical/prognostic relevance. Cancer Genomics Proteomics. 2010;7:67–73. doi: 10.1158/0008-5472.SABCS-09-3159
   PubMedGoogle Scholar
• Takayama K, Horie-Inoue K, Suzuki T, et al. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol. 2012;26(5):748–61. doi: 10.1210/me.2011-1242
   PubMedGoogle Scholar
• Song H, Liu C, Shen N, et al. Overexpression of TACC3 in breast cancer associates with poor prognosis. Appl Immunohistochem Mol Morphol. 2018;26(2):113–119. doi: 10.1097/PAI.0000000000000392
   PubMedGoogle Scholar
• Li Q, Ye L, Guo W, et al. Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer. Biochem Biophys Res Commun. 2017;486(4):872–878. doi: 10.1016/j.bbrc.2017.03.090
   PubMed Web of Science ®Google Scholar
• Du Y, Liu L, Wang C, et al. TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis. Oncotarget. 2016;7:41885–41897. doi: 10.18632/oncotarget.9628
   PubMedGoogle Scholar
• Yun M, Rong J, Lin ZR, et al. High expression of transforming acidic coiled coil-containing protein 3 strongly correlates with aggressive characteristics and poor prognosis of gastric cancer. Oncol Rep. 2015;34(3):1397–405. doi: 10.3892/or.2015.4093
   PubMed Web of Science ®Google Scholar
• Fang Z, Lin M, Chen S, et al. E2F1 promotes cell cycle progression by stabilizing spindle fiber in colorectal cancer cells. Cell Mol Biol Lett. 2022;27(1):90. doi: 10.1186/s11658-022-00392-y
   PubMed Web of Science ®Google Scholar
• Sabat-Pospiech D, Fabian-Kolpanowicz K, Prior IA, et al. Targeting centrosome amplification, an achilles’ heel of cancer. Biochem Soc Trans. 2019;47(5):1209–1222. doi: 10.1042/BST20190034
   PubMedGoogle Scholar
• Partch CL, Gardner KH. Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc Natl Acad Sci U S A. 2011;108(19):7739–44. doi: 10.1073/pnas.1101357108
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhou L, Pan L. Tumor-augmenting effect of histone methyltransferase WHSC1 on colorectal cancer via epigenetic upregulation of TACC3 and PI3K/Akt activation. Arch Med Res. 2022;53(7):658–665. doi: 10.1016/j.arcmed.2022.10.006
   PubMed Web of Science ®Google Scholar
• Shen C, Sheng Y, Zhu AC, et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell. 2020;27(1):64–80.e9. doi: 10.1016/j.stem.2020.04.009
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110. doi: 10.1038/nrg2936
   PubMed Web of Science ®Google Scholar
• Rio-Machin A, Ferreira BI, Henry T, et al. Downregulation of specific miRnas in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013;27(4):925–31. doi: 10.1038/leu.2012.302
   PubMed Web of Science ®Google Scholar
• Sun Y, Tian Y, Wang GZ, et al. Overexpression of transforming acidic coiled coil‑containing protein 3 reflects malignant characteristics and poor prognosis of glioma. Int J Mol Sci. 2017;18(3):235. doi: 10.3390/ijms18030235
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, et al. The FGFR Landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–67. doi: 10.1158/1078-0432.CCR-14-3212
   PubMed Web of Science ®Google Scholar
• Parker BC, Annala MJ, Cogdell DE, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 2013;123:855–65. doi: 10.1172/JCI67144
   PubMed Web of Science ®Google Scholar
• Charrasse S, Schroeder M, Gauthier-Rouviere C, et al. The TOGp protein is a new human microtubule-associated protein homologous to the xenopus XMAP215. J Cell Sci. 1998;111(Pt 10):1371–1383. doi: 10.1242/jcs.111.10.1371
   PubMedGoogle Scholar
• Royle SJ, Bright NA, Lagnado L. Clathrin is required for the function of the mitotic spindle. Nature. 2005;434(7037):1152–7. doi: 10.1038/nature03502
   PubMed Web of Science ®Google Scholar
• Nixon FM, Gutierrez-Caballero C, Hood FE, et al. The mesh is a network of microtubule connectors that stabilizes individual kinetochore fibers of the mitotic spindle. Elife. 2015;4. doi: 10.7554/eLife.07635
   PubMed Web of Science ®Google Scholar
• Booth DG, Hood FE, Prior IA, et al. A TACC3/ch-TOG/clathrin complex stabilises kinetochore fibres by inter-microtubule bridging. EMBO J. 2011;30(5):906–19. doi: 10.1038/emboj.2011.15
   PubMed Web of Science ®Google Scholar
• Fu W, Tao W, Zheng P, et al. Clathrin recruits phosphorylated TACC3 to spindle poles for bipolar spindle assembly and chromosome alignment. J Cell Sci. 2010;123(21):3645–51. doi: 10.1242/jcs.075911
   PubMed Web of Science ®Google Scholar
• Hubner NC, Bird AW, Cox J, et al. Quantitative proteomics combined with BAC TransgeneOmics reveals in vivo protein interactions. J Cell Bio. 2010;189(4):739–54. doi: 10.1083/jcb.200911091
   PubMed Web of Science ®Google Scholar
• Lin CH, Hu CK, Shih HM. Clathrin heavy chain mediates TACC3 targeting to mitotic spindles to ensure spindle stability. J Cell Bio. 2010;189(7):1097–105. doi: 10.1083/jcb.200911120
   PubMed Web of Science ®Google Scholar
• Ma MP, Robinson PJ, Chircop M. Sorting nexin 9 recruits clathrin heavy chain to the mitotic spindle for chromosome alignment and segregation. PLoS One. 2013;8(7):e68387. doi: 10.1371/journal.pone.0068387
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Ishidao T, Nomura T, et al. A B-Myb complex containing clathrin and filamin is required for mitotic spindle function. EMBO J. 2008;27(13):1852–1862. doi: 10.1038/emboj.2008.118
   PubMed Web of Science ®Google Scholar
• Shimizu H, Nagamori I, Yabuta N, et al. GAK, a regulator of clathrin-mediated membrane traffic, also controls centrosome integrity and chromosome congression. J Cell Sci. 2009;122(17):3145–52. doi: 10.1242/jcs.052795
   PubMed Web of Science ®Google Scholar
• Hood FE, Williams SJ, Burgess SG, et al. Coordination of adjacent domains mediates TACC3–ch-TOG–clathrin assembly and mitotic spindle binding. J Cell Bio. 2013;202(3):463–478. doi: 10.1083/jcb.201211127
   PubMed Web of Science ®Google Scholar
• Gard DL, Kirschner MW. A microtubule-associated protein from xenopus eggs that specifically promotes assembly at the plus-end. J Cell Bio. 1987;105(5):2203–15. doi: 10.1083/jcb.105.5.2203
   PubMed Web of Science ®Google Scholar
• Burgess SG, Peset I, Joseph N, et al. Aurora-A-Dependent control of TACC3 influences the rate of mitotic spindle assembly. PLoS Genet. 2015;11(7):e1005345. doi: 10.1371/journal.pgen.1005345
   PubMed Web of Science ®Google Scholar
• Gulluni F, Martini M, De Santis MC, et al. Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function. Cancer Cell. 2017;32(4):444–459.e7. doi: 10.1016/j.ccell.2017.09.002
   PubMed Web of Science ®Google Scholar
• Ryan EL, Shelford J, Massam-Wu T, et al. Defining endogenous TACC3–chTOG–clathrin–GTSE1 interactions at the mitotic spindle using induced relocalization. J Cell Sci. 2021;134(3). doi: 10.1242/jcs.255794
   Web of Science ®Google Scholar
• Liu A, Zeng S, Lu X, et al. Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer. Int J Biol Macromol. 2019;123:322–334. doi: 10.1016/j.ijbiomac.2018.11.032
   PubMed Web of Science ®Google Scholar
• Subhash VV, Tan SH, Tan WL, et al. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer. 2015;15(1):550. doi: 10.1186/s12885-015-1550-0
   PubMed Web of Science ®Google Scholar
• Nwagbara BU, Faris AE, Bearce EA, et al. TACC3 is a microtubule plus end–tracking protein that promotes axon elongation and also regulates microtubule plus end dynamics in multiple embryonic cell types. Mol Biol Cell. 2014;25(21):3350–3362. doi: 10.1091/mbc.E14-06-1121
   PubMed Web of Science ®Google Scholar
• Gutierrez-Caballero C, Burgess SG, Bayliss R, et al. TACC3–ch-TOG track the growing tips of microtubules independently of clathrin and aurora-A phosphorylation. Biol Open. 2015;4(2):170–179. doi: 10.1242/bio.201410843
   PubMed Web of Science ®Google Scholar
• Fu W, Chen H, Wang G, et al. Self-assembly and sorting of acentrosomal microtubules by TACC3 facilitate kinetochore capture during the mitotic spindle assembly. Proc Natl Acad Sci U S A. 2013;110(38):15295–300. doi: 10.1073/pnas.1312382110
   PubMed Web of Science ®Google Scholar
• Gergely F, Draviam VM, Raff JW. The ch-TOG/XMAP215 protein is essential for spindle pole organization in human somatic cells. Genes Dev. 2003;17(3):336–41. doi: 10.1101/gad.245603
   PubMed Web of Science ®Google Scholar
• Rajeev R, Mukhopadhyay S, Bhagyanath S, et al. TACC3–ch-TOG interaction regulates spindle microtubule assembly by controlling centrosomal recruitment of γ-TuRC. Biosci Rep. 2023;43(3). doi: 10.1042/BSR20221882
   PubMedGoogle Scholar
• Barros TP, Kinoshita K, Hyman AA, et al. Aurora A activates D-TACC–Msps complexes exclusively at centrosomes to stabilize centrosomal microtubules. J Cell Bio. 2005;170(7):1039–1046. doi: 10.1083/jcb.200504097
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Noetzel TL, Pelletier L, et al. Aurora a phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Bio. 2005;170(7):1047–55. doi: 10.1083/jcb.200503023
   PubMed Web of Science ®Google Scholar
• Foraker AB, Camus SM, Evans TM, et al. Clathrin promotes centrosome integrity in early mitosis through stabilization of centrosomal ch-TOG. J Cell Bio. 2012;198(4):591–605. doi: 10.1083/jcb.201205116
   PubMed Web of Science ®Google Scholar
• Singh P, Thomas GE, Gireesh KK, et al. TACC3 protein regulates microtubule nucleation by affecting γ-tubulin ring complexes. J Biol Chem. 2014;289(46):31719–31735. doi: 10.1074/jbc.M114.575100
   PubMed Web of Science ®Google Scholar
• Akbulut O, Lengerli D, Saatci O, et al. A highly potent TACC3 inhibitor as a novel anticancer drug candidate. Mol Cancer Ther. 2020;19(6):1243–1254. doi: 10.1158/1535-7163.MCT-19-0957
   PubMed Web of Science ®Google Scholar
• Rajeev R, Singh P, Asmita A, et al. Aurora a site specific TACC3 phosphorylation regulates astral microtubule assembly by stabilizing γ-tubulin ring complex. BMC Mol Cell Biol. 2019;20(1):58. doi: 10.1186/s12860-019-0242-z
   PubMed Web of Science ®Google Scholar
• Mori D, Yano Y, Toyo-Oka K, et al. NDEL1 phosphorylation by aurora-A kinase is essential for centrosomal maturation, separation, and TACC3 recruitment. Mol Cell Biol. 2007;27(1):352–67. doi: 10.1128/MCB.00878-06
   PubMed Web of Science ®Google Scholar
• Godinho SA, Pellman D. Causes and consequences of centrosome abnormalities in cancer. Philos Trans R Soc Lond B Biol Sci. 2014;369(1650):20130467. doi: 10.1098/rstb.2013.0467
   PubMed Web of Science ®Google Scholar
• Fukasawa K, Choi T, Kuriyama R, et al. Abnormal centrosome amplification in the absence of p53. Science. 1996;271(5256):1744–7. doi: 10.1126/science.271.5256.1744
   PubMed Web of Science ®Google Scholar
• Pannu V, Mittal K, Cantuaria G, et al. Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget. 2015;6(12):10487–97. doi: 10.18632/oncotarget.3402
   PubMedGoogle Scholar
• Gergely F, Basto R. Multiple centrosomes: together they stand, divided they fall. Genes Dev. 2008;22(17):2291–6. doi: 10.1101/gad.1715208
   PubMed Web of Science ®Google Scholar
• Fielding AB, Lim S, Montgomery K, et al. A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells. Oncogene. 2011;30(5):521–34. doi: 10.1038/onc.2010.431
   PubMed Web of Science ®Google Scholar
• Sadek CM, Jalaguier S, Feeney EP, et al. Isolation and characterization of AINT: a novel ARNT interacting protein expressed during murine embryonic development. Mech Dev. 2000;97(1–2):13–26. doi: 10.1016/s0925-4773(00)00415-9
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510–4. doi: 10.1073/pnas.92.12.5510
   PubMed Web of Science ®Google Scholar
• Guo Y, Partch CL, Key J, et al. Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small molecules. ACS Chem Biol. 2013;8(3):626–35. doi: 10.1021/cb300604u
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia — a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. doi: 10.1038/nrc704
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Yi Lee SH, Bartle N, et al. A classic zinc finger from friend of GATA mediates an interaction with the coiled-coil of transforming acidic coiled-coil 3. J Biol Chem. 2004;279(38):39789–39797. doi: 10.1074/jbc.M404130200
   PubMed Web of Science ®Google Scholar
• Garriga-Canut M, Orkin SH. Transforming acidic coiled-coil protein 3 (TACC3) controls friend of GATA-1 (FOG-1) subcellular localization and regulates the association between GATA-1 and FOG-1 during hematopoiesis. J Biol Chem. 2004;279(22):23597–605. doi: 10.1074/jbc.M313987200
   PubMed Web of Science ®Google Scholar
• Tsang AP, Visvader JE, Turner CA, et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell. 1997;90(1):109–119. doi: 10.1016/S0092-8674(00)80318-9
   PubMed Web of Science ®Google Scholar
• Wang X, Crispino JD, Letting DL, et al. Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. EMBO J. 2002;21(19):5225–34. doi: 10.1093/emboj/cdf527
   PubMed Web of Science ®Google Scholar
• Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer. 2010;1(12):1178–88. doi: 10.1177/1947601911404223
   PubMedGoogle Scholar
• He JC, Yao W, Wang JM, et al. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors. Oncotarget. 2016;7(46):75441–75456. doi: 10.18632/oncotarget.12254
   PubMedGoogle Scholar
• Wen YL, Yan SM, Wei W, et al. Transforming acidic coiled-coil protein-3: a novel marker for differential diagnosis and prognosis prediction in endocervical adenocarcinoma. Mol Med. 2021;27(1):60. doi: 10.1186/s10020-021-00298-z
   PubMed Web of Science ®Google Scholar
• Lauffart B, Vaughan MM, Eddy R, et al. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005;5(1):8. doi: 10.1186/1472-6874-5-8
   PubMedGoogle Scholar
• Jiang F, Kuang B, Que Y, et al. The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer. Oncol Rep. 2016;35(1):436–46. doi: 10.3892/or.2015.4373
   PubMed Web of Science ®Google Scholar
• Jung CK, Jung JH, Park GS, et al. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int. 2006;56(9):503–9. doi: 10.1111/j.1440-1827.2006.01998.x
   PubMed Web of Science ®Google Scholar
• Fan X, Liu B, Wang Z, et al. TACC3 is a prognostic biomarker for kidney renal clear cell carcinoma and correlates with immune cell infiltration and T cell exhaustion. Aging. 2021;13(6):8541–8562. doi: 10.18632/aging.202668
   PubMedGoogle Scholar
• Matsuda K, Miyoshi H, Hiraoka K, et al. Elevated expression of transforming acidic coiled-coil containing protein 3 (TACC3) is associated with a poor prognosis in osteosarcoma. Clin Orthop Relat Res. 2018;476(9):1848–1855. doi: 10.1097/CORR.0000000000000379
   PubMedGoogle Scholar
• Huang ZL, Lin ZR, Xiao YR, et al. High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget. 2015;6(9):6850–61. doi: 10.18632/oncotarget.3190
   PubMedGoogle Scholar
• Zhou DS, Wang HB, Zhou ZG, et al. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget. 2015;6(27):24163–77. doi: 10.18632/oncotarget.4643
   PubMedGoogle Scholar
• Moritsubo M, Miyoshi H, Matsuda K, et al. TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia/lymphoma patients. Int J Lab Hematol. 2020;42(6):842–848. doi: 10.1111/ijlh.13289
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–5. doi: 10.1126/science.1220834
   PubMed Web of Science ®Google Scholar
• Koutros S, Kiemeney LA, Pal Choudhury P, et al. Genome-wide association study of bladder cancer reveals new biological and translational insights. Eur Urol. 2023;84(1):127–137. doi: 10.1016/j.eururo.2023.04.020
   PubMed Web of Science ®Google Scholar
• Capelletti M, Dodge ME, Ercan D, et al. Identification of recurrent FGFR3–TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014;20(24):6551–6558. doi: 10.1158/1078-0432.CCR-14-1337
   PubMed Web of Science ®Google Scholar
• Tamura R, Yoshihara K, Saito T, et al. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 2018;7(1):4. doi: 10.1038/s41389-017-0018-2
   PubMedGoogle Scholar
• Chew NJ, Nguyen EV, Su SP, et al. FGFR3 signaling and function in triple negative breast cancer. Cell Commun Signal. 2020;18(1):13. doi: 10.1186/s12964-019-0486-4
   PubMed Web of Science ®Google Scholar
• Bielle F, Di Stefano AL, Meyronet D, et al. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. Brain Pathol. 2018;28(5):674–683. doi: 10.1111/bpa.12563
   PubMed Web of Science ®Google Scholar
• Kurobe M, Kojima T, Nishimura K, et al. Development of RNA-FISH assay for detection of oncogenic FGFR3-TACC3 fusion genes in FFPE samples. PloS One. 2016;11(12):e0165109. doi: 10.1371/journal.pone.0165109
   PubMed Web of Science ®Google Scholar
• Haura EB, Hicks JK, Boyle TA. erdafitinib overcomes FGFR3-TACC3–mediated resistance to osimertinib. J Thorac Oncol. 2020;15(9):e154–e156. doi: 10.1016/j.jtho.2019.12.132
   PubMed Web of Science ®Google Scholar
• Ou SI, Horn L, Cruz M, et al. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer. 2017;111:61–64. doi: 10.1016/j.lungcan.2017.07.006
   PubMed Web of Science ®Google Scholar
• Raphael A, Dudnik E, Hershkovitz D, et al. FGFR fusions as an acquired resistance mechanism following treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and a suggested novel target in advanced non-small cell lung cancer (aNSCLC). J Clin Med. 2022;11(9):2475. doi: 10.3390/jcm11092475
   PubMed Web of Science ®Google Scholar
• Di Stefano AL, Picca A, Saragoussi E, et al. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. Neuro Oncol. 2020;22(11):1614–1624. doi: 10.1093/neuonc/noaa121
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002–7. doi: 10.1158/1078-0432.CCR-09-0715
   PubMed Web of Science ®Google Scholar
• Suhail TV, Singh P, Manna TK. Suppression of centrosome protein TACC3 induces G1 arrest and cell death through activation of p38–p53–p21 stress signaling pathway. Eur J Cell Biol. 2015;94(2):90–100. doi: 10.1016/j.ejcb.2014.12.001
   PubMed Web of Science ®Google Scholar
• Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial–mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 2013;332(1):63–73. doi: 10.1016/j.canlet.2013.01.013
   PubMed Web of Science ®Google Scholar
• Yao R, Natsume Y, Saiki Y, et al. Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene. 2012;31:135–148. doi: 10.1038/onc.2011.235
   PubMed Web of Science ®Google Scholar
• Wurdak H, Zhu S, Min KH, et al. A small molecule accelerates neuronal differentiation in the adult rat. Proc Natl Acad Sci U S A. 2010;107(38):16542–7. doi: 10.1073/pnas.1010300107
   PubMed Web of Science ®Google Scholar
• Campo L, Breuer EK. Inhibition of TACC3 by a small molecule inhibitor in breast cancer. Biochem Biophys Res Commun. 2018;498(4):1085–1092. doi: 10.1016/j.bbrc.2018.03.125
   PubMed Web of Science ®Google Scholar
• Polson ES, Kuchler VB, Abbosh C, et al. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med. 2018;10(454). doi: 10.1126/scitranslmed.aar2718
   Web of Science ®Google Scholar
• Yao R, Kondoh Y, Natsume Y, et al. A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene. 2014;33(33):4242–4252. doi: 10.1038/onc.2013.382
   PubMed Web of Science ®Google Scholar
• Ohoka N, Nagai K, Hattori T, et al. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway. Cell Death Dis. 2014;5(11):e1513. doi: 10.1038/cddis.2014.471
   PubMedGoogle Scholar
• Schmidt S, Schneider L, Essmann F, et al. The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program. Oncogene. 2010;29(46):6184–92. doi: 10.1038/onc.2010.354
   PubMed Web of Science ®Google Scholar
• Yim EK, Tong SY, Ho EM, et al. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol Rep. 2009;21(2):549–557.
   PubMed Web of Science ®Google Scholar
• Ohoka N, Nagai K, Shibata N, et al. SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib. Cancer Sci. 2017;108(5):1032–1041. doi: 10.1111/cas.13198
   PubMed Web of Science ®Google Scholar
• Gedik ME, Saatci O, Oberholtzer N, et al. Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer. bioRxiv. 2023. doi: 10.1101/2023.09.12.557273
   PubMedGoogle Scholar
• Nelson KN, Meyer AN, Wang CG, et al. Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. Oncotarget. 2018;9(76):34306–34319. doi: 10.18632/oncotarget.26142
   PubMedGoogle Scholar
• Nelson KN, Meyer AN, Siari A, et al. Oncogenic gene fusion FGFR3-TACC3 is regulated by tyrosine phosphorylation. Mol Cancer Res. 2016;14(5):458–69. doi: 10.1158/1541-7786.MCR-15-0497
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Lau DK, Hodgson-Garms M, et al. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. BMC Cancer. 2022;22(1):478. doi: 10.1186/s12885-022-09478-4
   PubMed Web of Science ®Google Scholar
• Parker Kerrigan BC, Ledbetter D, Kronowitz M, et al. RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neurooncol Adv. 2020;2(1):vdaa132. doi: 10.1093/noajnl/vdaa132
   PubMedGoogle Scholar
• Li T, Mehraein-Ghomi F, Forbes ME, et al. HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion. Mol Ther. 2022;30(4):1610–1627. doi: 10.1016/j.ymthe.2022.02.009
   PubMed Web of Science ®Google Scholar